The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | MRD in AML clinical practice
Measurable residual disease (MRD) is rising in popularity as a prognostic indicator in a variety of blood cancer types. We spoke to Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about his experience of using MRD for acute myeloid leukemia (AML). He gives an overview of the predictive benefits of MRD in pre-transplant patients with both low- and high-risk AML, as well as the pros and cons of using flow cytometry vs. next-generation sequencing to detect MRD. Finally, Dr Guolo describes how MRD gives a better definition of complete response than morphological prognostic indicators.
